Baseline characteristics
schizophreniform disorder, psychotic disorder, ±, schizophrenia-spectrum, psychiatric, psychotic disorders, Schizophrenia, schizophrenia, DSM-5
The diagram of this trial is illustrated in Baseline demographic and clinical characteristics of participants among 6 trajectoriesAbbreviations: Full-time employment defined as having a job >15 h per week for more than 3 months during the past 6 months; Part-time employment defined as serving some duties or having a job but not meeting the requirement for full-time employment.Schizophrenia included schizophrenia and schizophreniform disorder; Other psychotic disorder included other schizophrenia-spectrum and other psychotic disorder based on DSM-5 criteria.Comparisons of demographic/clinical characteristics and changes between baseline and 2-year follow-up across 4 subgroupsAbbreviations: 
Schizophrenia includes schizophrenia and schizophreniform disorder, versus other schizophrenia-spectrum and other psychotic disorders.Full-time employment is defined as having a job >15 hours per week for more than 3 months during the past 6 months.Within a subgroup, the end-of-follow-up scores were statistically significantly different from their baseline scores compared to paired t-test.Two patients actually stopped medications on their own accord, the other four patients had relapsed and even resumed a dose higher than the baseline level.Excluding a case who started from exceptionally high baseline PANSS scores and then steadily decreased severity during the course until relapse, the remaining 5 failed reducers showed significant worsening in PANSS and PSP comparing their scores at baseline and at the time of relapse by paired t-test.Patients having a relapse did not report MSQ by that time.Statistics with The low baseline severity and relatively high personal social functioning suggest patients’ remitted states at the beginning of dose tapering. Durations of illness ranged widely from 0.8 to 35 years (mean 9.6 ± 8.5 years), and the majority had a history of psychiatric hospitalization (56.9%) and a history of relapse (66.7%). Baseline treatment comprised 10 oral and 2 long-acting injectable antipsychotics with dose ranges skewed to the lower end of each agent, with an average CPZE dose of around 200 mg/d (